Nurix Therapeutics (NRIX) Operating Income (2019 - 2026)
Nurix Therapeutics (NRIX) reported Operating Income of -$92.5 million for Q1 2026, down 47.14% year-over-year from -$175.0 million in Q1 2025, and down 11.31% quarter-over-quarter from -$83.1 million in Q4 2025.
Nurix Therapeutics (NRIX) Operating Income (2019 - 2026) Analysis & Trends
Nurix Therapeutics (NRIX) has 8 years of Operating Income data on file, last reported at -$92.5 million in Q1 2026.
- Operating Income for Q1 2026 came in at -$92.5 million, down 47.14% year-over-year; the trailing twelve-month figure through Feb 2026 was -$315.3 million (down 36.69% YoY), and the FY2025 annual result was -$285.7 million, down 34.1% from the prior year.
- Operating Income slipped to -$92.5 million in Q1 2026 per NRIX's latest filing, from -$83.1 million in the prior quarter.
- Over five years, Operating Income peaked at -$26.8 million in Q2 2023 and troughed at -$92.5 million in Q1 2026.
- A 5-year average of -$54.7 million and a median of -$48.3 million in 2025 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2024: Operating Income soared 41.45% in 2023, then plunged 81.36% in 2024.
- A 5-year view of Operating Income shows it stood at -$48.7 million in 2022, then increased by 6.89% to -$45.3 million in 2023, then tumbled by 42.62% to -$64.7 million in 2024, then retreated by 28.52% to -$83.1 million in 2025, then decreased by 11.31% to -$92.5 million in 2026.
- Business Quant data shows NRIX's Operating Income at -$92.5 million in Q1 2026, -$83.1 million in Q4 2025, and -$91.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Nurix Therapeutics | 1.93 Bn | 1.39 Bn | - | -92.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -92.50 Mn |
| Nov 30, 2025 | -83.10 Mn |
| Aug 31, 2025 | -91.39 Mn |
| May 31, 2025 | -48.32 Mn |
| Feb 28, 2025 | -62.86 Mn |
| Nov 30, 2024 | -64.66 Mn |
| Aug 31, 2024 | -54.61 Mn |
| May 31, 2024 | -48.54 Mn |
| Feb 29, 2024 | -45.22 Mn |
| Nov 30, 2023 | -45.33 Mn |
| Aug 31, 2023 | -40.01 Mn |
| May 31, 2023 | -26.77 Mn |
| Feb 28, 2023 | -42.95 Mn |
| Nov 30, 2022 | -48.69 Mn |
| Aug 31, 2022 | -46.72 Mn |
| May 31, 2022 | -45.72 Mn |
| Feb 28, 2022 | -42.74 Mn |
| Nov 30, 2021 | -37.95 Mn |
| Aug 31, 2021 | -29.00 Mn |
| May 31, 2021 | -26.41 Mn |